Skylark Bio Receives Unanimous DSMB Recommendation to Advance SKY-GJB2 to Younger Cohort in SONIX Phase 1/2 Trial for GJB2-Related Pediatric Deafness

CAMBRIDGE, Mass.–(BUSINESS WIRE)– #ClinicalResearch–Skylark Bio, a clinical-stage biotechnology company developing precision genetic medicines for hearing loss and other monogenic disorders, has received a unanimous recommendation from the independent Data Safety Monitoring Board (DSMB) to advance the SONIX Phase 1/2 clinical trial of SKY-GJB2, the Company’s investigational inner-ear-targeted gene therapy for GJB2-mediated hearing loss. After reviewing the safety data from the four pediatric participants aged 2
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks